Oncology Based In-vivo CRO Market Size, Share & Trends Analysis Report By Indication (Blood Cancer, Solid Tumor, Others), By Region)- Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

Oncology Based In-vivo CRO Market Size and Growth

The global oncology based In-vivo CRO market size was valued at USD 2.19 billion in 2023 and is anticipated to reach around USD 4.99 billion by 2033, growing at a CAGR of 8.59% from 2024 to 2033.

Oncology Based In-vivo CRO Market Report Highlights

• The solid tumors segment held the largest share of 47.89% owing to the increasing incidence of cancer across the globe, and the growing interest of world agencies such as the WHO in analyzing their prevalence, causative agents, and treatment options is boosting R&D
• Based on solid tumor-based model, patient-derived xenograft is anticipated to register the fastest CAGR of 9.21% over the forecast period
• North America accounted for the largest global share of 50.19% in 2023, with the major contributions from the U.S., owing to increased funding available in the region. This has boosted research activities. Major pharmaceutical and life sciences companies continue to drive market growth with their established presence in the region
• Asia Pacific is anticipated to register the fastest CAGR over the forecast period, owing to many developed countries investing in Asia Pacific regions and the various amendments made by the regulatory market to change the clinical trials evaluation standards according to the global platform

Oncology Based In-vivo CRO Market Growth 

The rising regularity with which big pharmaceutical companies outsource R&D activities, particularly in oncology, to focus on their core expertise is a significant market growth driver. Furthermore, the economic effectiveness of CROs, as opposed to completing an in-house study, would most certainly increase their demand during the predicted period.

Furthermore, the changing landscape of CROs and the rising need for diverse medications are projected to drive market expansion in the future years. In addition, biopharmaceutical and pharmaceutical investments in therapies drive R&D activities, as do drug development services. CROs have created their goods and services to assist manufacturers in getting traction with their R&D operations. Furthermore, economic instability is anticipated to boost outsourcing and contracting as biopharma and pharmaceutical companies address these problems. Small and medium-sized biopharmaceutical enterprises, in general, require more outsourcing due to limited resources.

Furthermore, due to their expertise and years of experience in the industry, CROs complete the assigned tasks at an extremely fast pace. According to a Tufts Center for the Study of Drug Development (CSDD) survey of top executives from major pharmaceutical companies, more than 75.0% believe CROs are more time-efficient than internal teams, boosting the demand for outsourcing.

Pharmaceutical companies are rapidly outsourcing R&D activities to CROs in order to remain competitive and agile in an era of expanding information, new technology, and volatile economic conditions. Companies prefer to outsource a wide range of activities from basic research to late-stage development, including target validation, hit exploration, lead optimization, genetic engineering, assay development safety, and efficacy tests in animal models as well as human clinical trials.

Oncology Based In-vivo CRO Market Report Scope

U.S. Oncology Based In-vivo CRO Market Size, Industry Report, 2033

The U.S. oncology based In-vivo CRO market size was valued at USD xx billion in 2023 and is projected to surpass around USD xx billion by 2033, registering a CAGR of xx% over the forecast period of 2024 to 2033.

The North America oncology based in-vivo CRO market held the largest revenue share of 50.19% globally in 2023. This can be attributed to technologically advanced CROs in this region. The U.S. has the highest per capita healthcare spending, and the availability of funding and grants from government organizations such as the National Institute of Health (NIH) promotes research activities. The trend for reducing the R&D cost is most common in major life sciences companies. Clinical trial sponsors are under pressure due to the increasing complexity of the research methodology to reduce time and cost. The increasing R&D activities and the need to reduce the overall trial expenditure are expected to drive the need for CROs in North America.

U.S. Oncology Based In-vivo CRO Market Trends

The U.S. oncology based in-vivo CRO market accounted for the largest revenue share in the North American region in 2023 owing to rising funding, established market players, and a growing pipeline of oncology drugs. In addition, the country has many market players offering comprehensive in-vivo CRO services for various cancer types. This significant presence of CRO service providers and increasing collaboration among research institutes has significantly increased the demand for these in-vivo CROs across oncology. For instance, in July 2023, The University of Texas MD Anderson Cancer Center & Nexo Therapeutics announced a collaboration to utilize innovative technology & capabilities of each organization at the earliest stages of drug discovery & development to rapidly advance new cancer therapies against undruggable targets.

Europe Oncology Based In-vivo CRO Market Trends

The Oncology based in-vivo CRO market in Europe is expected to grow significantly due to presence of a large number of CROs,growing focus on R&D activities, and increasing trend of outsourcing to European countries. This is expected to contribute to the increasing demand for the market in this region.

The Germany oncology-based in vivo CRO market held the largest share in the European region in 2023, owing to the government initiative for clinical research activities and rising strategic partnerships among companies. Besides, advancements in technology and growing research activities in oncology are expected to propel this market over the forecast period.  

The oncology-based in vivo CRO market in the UK is anticipated to grow over the forecast period owing to increased demand for CRO. To gain a larger market, further decreasing production costs by complying with the regulatory structure prevalent across the EU is expected to contribute to market growth.

Asia Pacific Oncology Based In-vivo CRO Market Trends

The oncology-based in vivo CRO market in Asia Pacific is expected to grow at a CAGR of 9.22% over the forecast period. The constant improvement in healthcare infrastructure, the presence of untapped opportunities, economic development, and a huge patient base are some factors responsible for the rapid growth. This region also ranks on top in ease of doing business. Moreover, with qualified labor and other resources available, Asia Pacific would be the key destination for in-vivo CRO projects over the forecast period.

The oncology based in vivo CRO market in China held the largest share in the Asia Pacific region in 2023 due to the growing focus on R&D of novel treatments, increasing pharmaceutical companies outsourcing, and higher cost efficiency provided by Chinese CROs.

The Japan oncology based in vivo CRO market is expected to grow over the forecast period due to the increasing demand for preclinical trials outsourcing and growing adoption of outsourcing models drive the market growth.

The oncology-based in vivo CRO market in India is anticipated to grow at the fastest CAGR over the forecast period, owing to the availability of established market players and rising oncology drug innovations. Besides, partnerships between pharma, biotech, and CROs drive the market.

Oncology Based In-vivo CRO Industry Dynamics

The oncology based in vivo CRO market growth stage is medium, and its pace is accelerating. The market is characterized by the level of M&A activities, the degree of innovation, the impact of regulations, product expansions, and regional expansions.

The oncology-based in vivo CRO product categories have observed advancements due to the increasing frequency of outsourcing of R&D activities by various pharmaceutical companies. This further supports the development of the most efficient, relevant study design and screening method to identify various compounds and optimize lead candidates.

The growing presence of market players has made the market more competitive, leading to a rise in mergers and acquisitions. Besides, the market has been proven to facilitate gains, leadership retention, or international expansion.

Regulatory bodies and other authorities can influence the oncology-based in vivo CRO market. These regulations support the production of various oncology drugs using in vivo models.

Rising expansions, increasing R&D activities, and rising demand for various oncology-based drugs have led to a rise in demand for in-vivo CRO, further positively influencing the market dynamics.

The increase in R&D expenditure, the existence of technologically advanced service providers, and the rising requirement for oncology-based drugs have led the market growth.

Oncology-Based In-vivo CRO Market Trends

The oncology-based in-vivo Contract Research Organization (CRO) market is witnessing significant growth and transformation. Several key trends are shaping this market, driven by the increasing complexity of cancer treatments and the demand for specialized research services.

• Rising Demand for Oncology Research: With cancer being a leading cause of mortality worldwide, there is a heightened demand for innovative treatments and therapies. This has led pharmaceutical and biopharmaceutical companies to invest heavily in oncology research, increasingly relying on CROs for in-vivo studies to accelerate drug development.
• Specialization and Expertise: As cancer treatments become more personalized, the need for specialized CROs with expertise in specific types of cancer and advanced technologies has grown. CROs offering niche services, such as immuno-oncology, gene therapy, and precision medicine, are particularly in demand.
• Advanced Technologies and Methodologies: The adoption of cutting-edge technologies, such as CRISPR gene editing, next-generation sequencing, and advanced imaging techniques, is becoming prevalent in oncology research. CROs are investing in these technologies to provide more accurate and comprehensive data, enhancing the quality of preclinical studies.
• Increased Outsourcing by Small and Mid-Sized Biopharma Companies: Smaller biopharma companies, often with limited resources, are increasingly outsourcing their R&D activities to CROs. This allows them to access advanced facilities and expertise without the need for substantial capital investment, enabling them to focus on core competencies.
• Regulatory and Ethical Considerations: The regulatory landscape for oncology research is becoming more stringent, with increased scrutiny on the ethical aspects of in-vivo studies. CROs are adapting by implementing more rigorous compliance protocols and adopting humane practices in animal research, aligning with the growing emphasis on ethical standards.
• Global Expansion and Collaboration: The oncology-based in-vivo CRO market is expanding globally, with significant growth in regions such as Asia-Pacific and Europe. CROs are establishing partnerships and collaborations with local research institutions and pharmaceutical companies to tap into these markets and enhance their global reach.
• Impact of COVID-19: The COVID-19 pandemic has had a profound impact on the oncology-based in-vivo CRO market. While it initially disrupted clinical trials and research activities, it also highlighted the importance of flexible and adaptive research models. CROs have responded by adopting virtual and decentralized trial models, which are expected to continue beyond the pandemic.

Oncology Based In-vivo CRO Market By Indication Insights

Based on indication, the market is segmented into blood cancer, solid tumors, and others. In 2023, the solid tumor tests segment accounted for the largest revenue share of 47.89%. The segment is also anticipated to register the fastest CAGR growth over the forecast period. The factor responsible for higher research in solid tumors is the presence of over 800 new molecules in the research pipeline undertaken by large pharmaceutical companies. Furthermore, the availability of grants from institutes such as NIH and NCI, and the existing gap between the demand and supply of treatments for solid cancer also remain promising drivers of growth. Solid tumors are abnormal tissue mass that grows during cancer and affects various body parts, including organs, muscles, and bones. These are generally addressed as carcinomas and sarcomas.

The blood cancer segment is anticipated to grow at a CAGR of 8.76% over the forecast period. The rapid rise in investigational molecules for oncology and research in stem cells is anticipated to promote high investment within the in-vivo space for oncology. Blood cancer is inclusive of all the tumors that are either generated in the blood or have the capability to migrate within the blood system. Broadly, these comprise myelomas, lymphomas, and leukemia. This is expected to drive the market over the forecast period.

Oncology Based In-vivo CRO Market Top Key Companies:

• Charles River Laboratory
• ICON Plc
• Thermo Fisher Scientific Inc.
• Eurofins Scientific
• Taconic Biosciences
• Crown Bioscience
• LabCorp
• WuXi AppTec
• EVOTEC
• The Jackson Laboratory

Oncology Based In-vivo CRO Market Recent Developments

In November 2023, Crown Bioscience launched the OrganoidXploreTM service. It is an organoid panel screening platform service that offers robust, reproducible, and clinical output at record speed, propelling preclinical oncology drug discovery and reshaping the landscape of cancer treatment development.

In October 2023, Coeptis Therapeutics Holdings, Inc. announced research demonstrating the possibility of the SNAP-CAR T-cell platform to target numerous antigens. The research involved SNAP-CAR to demonstrate the technology's adaptable antigen-targeting abilities in vivo and in-vitro in xenograft models of human tumors.

Oncology Based In-vivo CRO Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Oncology Based In-vivo CRO market.

By Indication 

• Blood cancer
  • Syngeneic model
  • Patient-derived Xenograft
  • Xenograft
• Solid tumors
  • Syngeneic model
  • Patient-derived Xenograft
  • Xenograft
• Others
  • Syngeneic model
  • Patient-derived Xenograft
  • Xenograft

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)